NCT04772248View on ClinicalTrials.gov

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

CompletedOBSERVATIONAL

Enrollment

105,711

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tofacitinib

First eligible prescription for treating rheumatoid arthritis (RA)

DRUG

TNF Inhibitor

First eligible prescription for treating rheumatoid arthritis (RA)

Trial Locations (1)

02120

Brigham And Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04772248 - Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints | Biotech Hunter | Biotech Hunter